The activin/myostatin axis studied to preserve muscle during GLP-1 weight loss.
Last updated
The GLP-1 era created a new research question: not just how much weight comes off, but what kind. Across trials, roughly a quarter to 40% of the weight lost on semaglutide and tirzepatide is lean mass rather than fat — a concern about the *quality* of weight loss as these drugs scale to tens of millions of people. This area collects the compounds studied to keep the muscle while the fat goes.
Almost all of them act on a single control system: the activin/myostatin axis. Myostatin and activin A are TGF-β-superfamily brakes on muscle growth that signal through the activin type II receptors (ActRII) and the Smad2/3 pathway; follistatin is the body’s natural antagonist. The therapeutic strategy is to release that brake — with ligand-neutralizing antibodies (trevogrumab against myostatin, garetosmab against activin A), a precursor-selective antibody (apitegromab), or a receptor blocker (bimagrumab) — usually on top of an incretin drug. The clinical readouts converge: in the Phase 2 COURAGE and EMBRAZE trials, adding these agents preserved roughly half to 80% of the lean mass that a GLP-1 drug alone would have cost. None is yet approved for muscle preservation, though garetosmab (Pasatru) reached FDA approval in August 2026 for the rare bone disease FOP — the first drug of the axis to reach the market.
The body’s brake on muscle growth — a TGF-β-family growth factor whose inhibition is the leading strategy to preserve muscle, including during GLP-1 weight loss.
View profileA natural myostatin and activin antagonist — by neutralizing the muscle brake it is one of the most potent pro-muscle factors studied, and a doping and gene-therapy flashpoint.
View profileA monoclonal antibody that selectively blocks pro/latent myostatin — the muscle brake — studied to preserve lean mass during GLP-1 weight loss.
View profileAn anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.
View profileA "sweeping" anti-myostatin antibody (Roche/Chugai) that not only blocks but actively clears myostatin — a cautionary case after its rare-disease trials failed.
View profileAn anti-activin-A antibody (Regeneron) — the first drug on the whole activin/myostatin axis to reach FDA approval (as Pasatru, for the rare bone disease FOP), and the activin-A leg of obesity muscle-preservation combinations.
View profileAn antibody that blocks the activin type II receptor itself — shutting off myostatin AND activin signaling at once; famous for adding muscle while cutting fat.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profileThe only hormone that makes you hungry — a stomach peptide, uniquely fatty-acid-modified, that drives appetite and also releases growth hormone.
View profileSome lean-mass loss accompanies the large weight loss they produce. Trial body-composition substudies put lean tissue at roughly a quarter to 40% of the total weight lost on semaglutide and tirzepatide — broadly similar to the muscle lost in diet-based weight loss, but at a much larger scale of use. This is a research reference, not medical advice.
The leading strategy targets the activin/myostatin axis: antibodies against myostatin (trevogrumab, apitegromab) or activin A (garetosmab), and the receptor blocker bimagrumab, usually added on top of a GLP-1 drug. Myostatin and follistatin are the underlying biology; follistatin gene therapy is a separate, earlier-stage approach.
In the Phase 2 COURAGE trial, adding trevogrumab to semaglutide preserved an estimated 50–80% of the lean mass otherwise lost, and the trevogrumab + garetosmab triplet preserved about 80.9% (with more tolerability-driven dropouts). In EMBRAZE, apitegromab preserved 54.9% of the lean mass otherwise lost on tirzepatide. These are Phase 2 results, not approvals.
Not for muscle preservation. Garetosmab (Pasatru) was FDA-approved in August 2026 for the rare bone disease FOP — the first agent of the axis to reach the market — and apitegromab is under FDA review for spinal muscular atrophy. Their obesity and muscle-preservation uses remain investigational. The pathway is also banned in sport.
How to weigh this evidence
Preclinical, observational, and randomized findings carry very different weight. The evidence hierarchy shows how to rank what you read before drawing conclusions.
Put the science to work — interactive utilities that run right here.
Ask in plain language — citation-backed answers from PubMed, PubChem & trials.
Build a peptide residue by residue with live chemistry, challenges & XP.
Sequence properties — pI, ε280, net charge & synthesis-difficulty flags.
Paste a certificate of analysis; grade its transparency and spot red flags.
Dose, dilution and syringe-unit math for reconstituting a vial.
Verified peptide monographs plus a live PubChem compound lookup.
Which peptides are best studied for muscle preservation & lean mass, how they compare, and what the clinical evidence shows — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.